<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" 
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://openbell.ai/</loc>
    <lastmod>2026-11-16T00:38:26.841Z</lastmod>
    <changefreq>hourly</changefreq>
    <priority>1.0</priority>
  </url>
  <url>
    <loc>https://openbell.ai/support</loc>
    <lastmod>2026-11-16T00:38:26.841Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.7</priority>
  </url>
  <url>
    <loc>https://openbell.ai/privacy</loc>
    <lastmod>2026-11-16T00:38:26.841Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://openbell.ai/terms</loc>
    <lastmod>2026-11-16T00:38:26.841Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://openbell.ai/feed.json</loc>
    <lastmod>2026-11-16T00:38:26.841Z</lastmod>
    <changefreq>hourly</changefreq>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://openbell.ai/news/NVDA:1794789048987</loc>
    <lastmod>2026-11-16T00:30:48.987Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/NVDA/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Social Media Discussion: $NVDA</image:title>
      <image:caption>**Sentiment: Neutral.** **Key theme:** Nvidia’s upcoming earnings call and speculation about Jensen Huang’s role, alongside debate over chip demand, export controls, and circular financing.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/NBIS:1794772896000</loc>
    <lastmod>2026-11-15T20:01:36.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/NBIS/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Nebius Group Reports Q3 2026 Earnings and Updates 2026 Revenue Guidance</image:title>
      <image:caption>Nebius Group reported Q3 2026 results that exceeded market estimates, but its shares fell 17% after management narrowed its 2026 revenue outlook. The company cited delays in bringing new data center capacity online and higher capital expenditure forecasts. Investors also raised concerns about future financing needs tied to the planned capacity expansion.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/DRTS:1794769302000</loc>
    <lastmod>2026-11-15T19:01:42.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/DRTS/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Alpha Tau Medical Announces Positive Interim Results from U.S. REGAIN Trial for Recurrent Glioblastoma</image:title>
      <image:caption>Alpha Tau Medical reported interim results from its U.S. REGAIN trial of Alpha DaRT for recurrent glioblastoma: all eight treated patients were alive as of November 11, 2026. Among six evaluable patients, the objective response rate was 100%, with five complete responses and one partial response, after a median follow-up of 6.9 months. The trial met its feasibility and safety endpoints, with successful deployment in all patients and no unanticipated serious adverse events. The company plans to discuss the results on a November 16 conference call; the article did not report financial results or a stock-price move.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/AUUD:1794751463000</loc>
    <lastmod>2026-11-15T14:04:23.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/AUUD/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Auddia Inc. Reports Third Quarter 2026 Financial Results</image:title>
      <image:caption>Auddia Inc. reported third-quarter 2026 revenue of $10,000, up from $0 in the year-earlier quarter. Its operating loss narrowed to $2.18 million from $2.37 million, while diluted EPS improved to -$0.36 from -$12.23.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/PFSA:1794751457000</loc>
    <lastmod>2026-11-15T14:04:17.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/PFSA/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Profusa Reports Third Quarter 2026 Financial Results</image:title>
      <image:caption>Profusa reported no revenue for the third quarter ended September 30, 2026, unchanged from the prior-year period. Its operating loss narrowed to $4.85 million from $21.7 million a year earlier. Diluted EPS was -$6.23, compared with -$6,167.85 in the prior-year quarter.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/CTNT:1794751449000</loc>
    <lastmod>2026-11-15T14:04:09.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/CTNT/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Cheetah Net Supply Chain Service Inc. Announces Third Quarter 2026 Results</image:title>
      <image:caption>Cheetah Net Supply Chain Service reported third-quarter 2026 revenue of $3.56 million, up from $361,935 a year earlier, and a net loss from continuing operations of $2.55 million versus $1.31 million. Its international trading segment generated $4.43 million in revenue during the first nine months, largely following the May acquisition of Super International. Logistics and warehousing revenue was nil for the quarter after the disposition of Edward and the expiration of legacy customer contracts. The company described the results as progress in diversifying its business; no stock-price impact was reported.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/NVVE:1794751445000</loc>
    <lastmod>2026-11-15T14:04:05.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/NVVE/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Nuvve Holding Corp. Reports Third Quarter 2026 Financial Results</image:title>
      <image:caption>Nuvve Holding Corp. reported third-quarter 2026 revenue of $1.09 million, down 31.9% from $1.60 million a year earlier, and a net loss of $4.69 million versus $4.79 million. Revenue included $604,190 from products, $265,156 from services and $219,646 in grants; SG&amp;A expenses were $4.15 million and R&amp;D expenses were $457,472. The company had 29.9 megawatts under management, up 5.7% from the fourth quarter of 2025, and raised $0.97 million in gross proceeds through financing activities during the quarter.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/GOVX:1794751442000</loc>
    <lastmod>2026-11-15T14:04:02.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/GOVX/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>GeoVax Labs Reports Third Quarter 2026 Financial Results</image:title>
      <image:caption>GeoVax Labs reported a third-quarter 2026 net loss of $4.2 million, or $10.56 per share, versus a $6.3 million loss a year earlier, with no revenue. Research and development expenses fell 44.1% year over year, reflecting the end of a BARDA contract and lower costs for GEO-CM04S1 and Gedeptin, partly offset by higher GEO-MVA manufacturing costs. The company discontinued its GEO-CM04S1 COVID-19 vaccine candidate to focus on GEO-MVA and Gedeptin. GeoVax had $2.2 million in cash at September 30, plus a $1 million revolving loan, which it expects to fund operations only through December 2026, raising substantial doubt about its ability to continue as a going concern.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/SQFT:1794751442000</loc>
    <lastmod>2026-11-15T14:04:02.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/SQFT/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Presidio Property Trust Reports 2026 Third Quarter Financial Results</image:title>
      <image:caption>Presidio Property Trust reported third-quarter 2026 revenue of $2.98 million, down 29.0% year over year, and operating profit of $1.90 million, down 28.4%. Its operating margin edged up to 64.0% from 63.4%, while diluted results shifted to a loss of $0.84 per share from earnings of $1.53 per share in the year-earlier quarter.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/FLYE:1794751440000</loc>
    <lastmod>2026-11-15T14:04:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/FLYE/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Fly-E Group, Inc. Announces Second Quarter and First Half of Fiscal Year 2027 Financial Results</image:title>
      <image:caption>Fly-E Group reported unaudited second-quarter fiscal 2027 revenue of $2.6 million, down 33.7% from $3.9 million a year earlier, while retail sales revenue fell 77.4% to $0.5 million. The company attributed the declines mainly to reducing its store count to four from 11; unit sales also fell to 7,392 from 18,564. For the first half of fiscal 2027, Fly-E recorded a net loss of $5.6 million and negative EBITDA of $4.7 million.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/MEDS:1794751435000</loc>
    <lastmod>2026-11-15T14:03:55.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/MEDS/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>DataMEDS AI, Inc. Reports Third Quarter 2026 Financial Results</image:title>
      <image:caption>DataMEDS AI reported third-quarter 2026 net operating profit of $10.535 million, versus a $34.318 million loss a year earlier, and earnings of $2.72 per share compared with a $23.07 per-share loss. The company attributed the turnaround to extinguishing debt and liabilities tied to prior management and cutting administrative expenses and management compensation. It also signed a non-binding memorandum of understanding with a Florida-based HMO to deploy its “Health Lives Here” application to more than 25,000 members, with definitive agreements expected in the fourth quarter of 2026.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/OBAI:1794751435000</loc>
    <lastmod>2026-11-15T14:03:55.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/OBAI/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Our Bond, Inc. Reports Third Quarter 2026 Financial Results and Business Update</image:title>
      <image:caption>Our Bond, Inc. reported third-quarter 2026 revenue of $2.5 million, up 19% sequentially, while subscription revenue increased 41%. Bookings totaled $3.1 million, compared with $2.6 million in the year-earlier quarter. The company plans to cut annualized operating costs by $6 million, including $3 million in recurring savings from AI and operational efficiencies. Its city-funded personal security program reached 60% adoption in a municipality of 270,000 residents, and the company is pursuing B2G2C opportunities in France, Israel, and the U.S.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/NAII:1794751434000</loc>
    <lastmod>2026-11-15T14:03:54.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/NAII/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Natural Alternatives International, Inc. Announces Fiscal 2027 Q1 Results</image:title>
      <image:caption>Natural Alternatives International reported fiscal 2027 first-quarter net sales of $28.1 million, down 25.5% from $37.7 million a year earlier, and a net loss of $2.5 million, or $0.41 per diluted share, compared with a $0.3 million loss, or $0.05 per share. Private-label contract manufacturing sales fell 29.1%, as several large customers reduced orders amid excess inventory and delayed product launches; new customer launches partly offset the decline. CarnoSyn beta-alanine royalty, licensing, and raw-material revenue rose 54.0% to $2.6 million, driven by higher TriBsyn sales.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/MDBH:1794751432000</loc>
    <lastmod>2026-11-15T14:03:52.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/MDBH/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>MDB Capital Holdings Reports Third Quarter 2026 Financial Results</image:title>
      <image:caption>MDB Capital Holdings reported zero revenue for the third quarter ended September 30, 2026, unchanged from the prior-year quarter. It posted an operating loss of $575,000, versus operating profit of $1.25 million a year earlier, and diluted EPS was a loss of $1.57 compared with earnings of $0.46 in the third quarter of 2025.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/DSS:1794751422000</loc>
    <lastmod>2026-11-15T14:03:42.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/DSS/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>DSS, Inc. Reports Third Quarter 2026 Financial Results</image:title>
      <image:caption>DSS, Inc. reported third-quarter 2026 revenue of $3.6 million, down 43.6% year over year. Its operating loss widened to $4.17 million from $3.23 million a year earlier, while diluted EPS was -$0.46 versus -$0.25. The company disclosed the results in its 10-Q filing released November 13, 2026.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/GWH:1794751421000</loc>
    <lastmod>2026-11-15T14:03:41.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/GWH/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>ESS Tech Files for Chapter 7 Bankruptcy and Ceases Operations</image:title>
      <image:caption>ESS Tech, an iron flow battery company, filed for Chapter 7 bankruptcy after considering its strategic alternatives and ceased operations, terminating all employees and officers without cause. The company was delisted from the New York Stock Exchange in early October 2026 and had since traded over the counter. ESS Tech was valued at approximately $1.1 billion when it merged with ACON S2 Acquisition Corp. in 2021, and its investors included SoftBank Group.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/GG:1794751373000</loc>
    <lastmod>2026-11-15T14:02:53.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/GG/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Golconda Gold Releases Q1 2026 Production Update and Announces Record Quarterly Production at the Galaxy Gold Mine</image:title>
      <image:caption>Golconda Gold Ltd. reported record quarterly production at its Galaxy Gold Mine in South Africa during the first quarter of 2026. The company said the result reflects its efforts to expand gold output under a self-funded growth strategy; the update did not provide production figures or financial results.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/CDNL:1794751354000</loc>
    <lastmod>2026-11-15T14:02:34.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/CDNL/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Cardinal Infrastructure Group Reports Q3 Earnings Miss, Withdraws Guidance, and Postpones Acquisition</image:title>
      <image:caption>Cardinal Infrastructure Group reported a third-quarter statutory loss of $0.21 per share, versus analyst expectations for a profit, while revenue was $202 million—14% below forecasts. The company said its EBITDA margin fell to 4.2%, issued a profit warning, and withdrew its full-year guidance. It also postponed a planned $357 million acquisition as it prioritizes operational recovery and margin stabilization.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/BAH:1794751300000</loc>
    <lastmod>2026-11-15T14:01:40.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/BAH/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Booz Allen Hamilton Awarded Major Defense and AI Contracts</image:title>
      <image:caption>Booz Allen Hamilton won a $1.6 billion contract to provide AI-driven technology supporting Weapons of Mass Destruction programs and human analysis capabilities. It also received a $16.3 billion contract associated with the Sentinel ICBM system, extending its work on U.S. national security and nuclear infrastructure. The article reports no financial results or stock-price impact.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/SMMT:1794751295000</loc>
    <lastmod>2026-11-15T14:01:35.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/SMMT/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application</image:title>
      <image:caption>Summit Therapeutics said the FDA issued a Complete Response Letter for its application seeking approval of ivonescimab with platinum-containing chemotherapy for certain patients with locally advanced or metastatic NSCLC previously treated with EGFR tyrosine kinase inhibitors. The FDA determined the application cannot be approved in its current form, and Summit must address the issues raised to determine the next steps in the regulatory process. The article did not report financial figures or a stock-price reaction.</image:caption>
    </image:image>
  </url>
</urlset>